Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

The Motley Fool has positions in and recommends AbbVie, Amgen, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Fed Chairman Jerome Powell Warns Trump's Tariffs Could ...